X

Trial Profile

Phase 1b Study of HSP90 Inhibitor, AT13387 (Onalespib) in Combination With Paclitaxel in Patients With Advanced, Triple Negative Breast Cancer

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 08 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Onalespib (Primary) ; Paclitaxel (Primary)
Indications Advanced breast cancer; Carcinoma; Male breast cancer; Triple negative breast cancer
Focus Adverse reactions

Most Recent Events

03 Nov 2022 Status changed from active, no longer recruiting to discontinued.
05 Jan 2022 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2022.
02 Jan 2021 Planned primary completion date changed from 31 Dec 2020 to 31 Dec 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com